Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.[1]

Vorozole
Clinical data
Other namesR-76713; Rizivor
ATC code
Pharmacokinetic data
BioavailabilityVery high
MetabolismHepatic
Elimination half-life8 hours
Identifiers
  • 6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H13ClN6
Molar mass324.77 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)[C@@H](c2ccc3nnn(c3c2)C)n4ncnc4
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.